Informace o publikaci

Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry

Autoři	VENCLÍČEK Ondřej SKŘIČKOVÁ Jana BRAT Kristián FISCHER Ondrej HAVEL Libor HRNCIARIK Michal MAREL Miloslav OPALKA Petr KRAKOROVA Gabriela ROZSIVALOVA Denisa KULTAN Juraj MULLEROVA Andrea ZARNAYOVA Lydia SMICKOVA Petra VASAKOVA Martina GYORFY Zsuzsanna JIROUSEK Michal KREJCI Daniel KREJCI Jana ZUNA Petr SVATON Martin HRDA Kristyna DUBA Jaroslav ALAHAKOON Jana SVOBODA Michal SILAR Jiri
Rok publikování	2021
Druh	Článek v odborném periodiku
Časopis / Zdroj	Anticancer Research
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://ar.iiarjournals.org/content/41/11/5549
Doi	http://dx.doi.org/10.21873/anticanres.15368
Klíčová slova	Lung cancer; non-smokers; clinical registry; NSCLC; survival; driving mutations
Popis	Background/Aim: LUCAS is a clinical lung cancer registry (ClinicalTrials.gov identifier is NCT04228237), prospectively collecting data from newly diagnosed lung cancer patients in seven pneumooncology centers in the Czech Republic, since June 1, 2018. The aim of the study was to assess the stage of the disease at the time of diagnosis, percentage of morphological types, survival, percentage of driving mutations, eligibility for radical surgery, and percentage of patients who undergo radical surgery, in the non-smoking population in comparison with smokers and former smokers. Patients and Methods: The total number of patients in the registry at the time of the analysis was 2,743. Only 2,439 patients with complete records (smoking status, stage, and type of tumor) were included in this study. Results: The analysis indicated that non-smokers are diagnosed at a later stage of the disease but they have a better survival rate than smokers. Fewer smokers with stage III disease who are eligible for radical surgery will undergo surgery compared to non-smokers with the same clinical stage. Driving mutations are more common in non-smokers, even after adjustment for the more frequent occurrence of adenocarcinoma in the group of non-smokers. Conclusion: The data from LUCAS registry are consistent with already known facts, suggesting that the LUCAS registry is a useful clinical tool.